medigraphic.com
Anales de la Sociedad Mexicana de Oftalmología y Archivos de la Asociación Para Evitar la Ceguera en México

2019, Number 3

<< Back Next >>

Rev Mex Oftalmol 2019; 93 (3)

Short-term safety of 2 mg of intravitreal ziv-aflibercept in different retinal pathologies

Meza-Anguiano A, Romo-García E, Gutiérrez-Ruiz GN, Paz-Camacho S, Quiñonez-Quiñonez W, Barrera-De León JC, Ramón-Concepción A, Romero-Mendizábal TJ, Sital-Gastelum S

Language: Spanish
References: 17
Page: 125-129
PDF size: 142.50 Kb.


ABSTRACT

Purpose: To assess the safety and effectiveness of 2 mg ziv-ablifercept (ZA) in different retinal diseases. Methods: Single arm, open-label, prospective study. A 2 mg (0.08 mL) ZA dose was administered following the hospital protocols for topical anesthesia. The following were considered adverse effects: IOP ›3 mmHg from baseline, retinal detachment, vitreous hemorrhage, endophthalmitis, retinal vasculitis, retinal necrosis, cataract progression, anterior and posterior uveitis. Results: The study included 91 eyes of 55 patients and 50% were men, with a median age of 64.26 ± 11.86 years, a mean of 1.68 ± 0.91 injections; baseline central foveal thickness (CFT) of 390. 91 ± 162.01 microns compared to a final CFT of 319.02 ± 104.67 microns (p = 0.000). Baseline best corrected visual acuity (BCVA) in logMAR was 0.86 ± 0.49 compared to a final BCVA of 0.75 ± 0.48 (p = 0.000). No adverse effects were reported. Conclusions: ZA is a safe and effective medication for the treatment of macular edema, regardless of the etiology, and it is also an affordable medication. Long-term studies are needed to evaluate its effectiveness compared to those drugs already approved for intravitreal use.


REFERENCES

  1. De Oliveira Dias JR, Andrade GC, Novais EA, Farah ME, Rodrigues EB. Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept. Int J Retina Vitreous. 2016;2:3.

  2. De Oliveira-Dias JR, Xavier CO, Maia A, de Moraes NS, Meyer C, Farah ME, Rodrigues EB. Intravitreal injection of ziv-aflibercept in patient with refractory age-related macular degeneration. Ophthalmic Surg Lasers Imaging Retina. 2015;46;91-4.

  3. De Andrade GC, de Oliveira_Dias JR, Maia A, Farah ME, Meyer CH, Rodrigues EB. Intravitreal injections of ziv-aflibercept for diabetic macular edema: a pilot study. Retina. 2016;36;1640-5.

  4. HodjatJalali K, Mehravaran S, Faghihi H, Hashemi H, Kazemi P, Rastad H. Intravitreal injection of ziv-aflibercept in the treatment of choroidal and retinal vascular diseases. J Curr Ophthalmol. 2017;29;228-31.

  5. Mansour AM, Al-Ghadban SI, Yunis MH, El-Sabban ME. Ziv-aflibercept in macular disease. B J Ophthalmol. 2015;99;1055-9.

  6. Videkar C, Kapoor A, Chhablani J, Narayanan R. Ziv-aflibercept: a novel option for the treatment of polypoidal choroidal vasculopathy. BMJ Case Rep. 2015;18;2015.

  7. Ozkaya A, Tulu B, Garip R. Aflibercept in macular edema secondary to retinal vein occlusion: A real life study. Saudi J Ophthalmol. 2017;31;211-5.

  8. Braimah IZ, Stewart M, Videkar C, Dedhia CJ, Chhablani J. Intravitreal ziv-aflibercept for the treatment of choroidal neovascularisation associated with conditions other than age-related macular degeneration. Br J Ophthalmol. 2017;101;1201-5.

  9. Braimah IZ, Agarwal K, Mansour A, Chhablani J. One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration. Br J Ophthalmol. 2018;102;91-6.

  10. Malik D, Tarek M, del Carpio JC, Ramirez C, Boyer D, Kenney MC, Kuppermann BD. Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture. Br J Ophthalmol. 2014;98;i11-6.

  11. Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, et al. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. N Engl J Med. 2015;372;1193-203.

  12. Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, et al. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology. 2016;123;1351-9.

  13. De Oliveira Dias JR, de Andrade GC, Kniggendorf VF, Novais EA, Maia A, Meyer C, et al. Clinical and electrophysiological evaluation after intravitreal ziv-aflibercept for exudative age-related macular degeneration. Retina 2017; 37:1499-1507

  14. Mansour AM Ashraf M, Dedhia CJ, Charbaji A, Souka AA, Chhablani J. Long-term safety and efficacy of ziv-aflibercept in retinal diseases. Br J Ophthalmol. 2017;101;1374-6.

  15. Kniggendorf VF, Novais EA, Maia A, Meyer C, Watanabe SE, Farah ME, Rodrigues EB. Clinical and electrophysiological evaluation after intravitreal ziv-aflibercept for exudative age-related macular degeneration. Retina. 2017; 37;1499-507.

  16. Chhablani J, Narayanan R, Mathai A, Yogi R, Stewart M. Short-term safety profile of intravitreal ziv-aflibercept. Retina. 2016;36;1126-31.

  17. Chhablani J, Dedhia CJ, Peguda HK, Stewart M. Short-term safety of 2 mg intravitreal ziv-aflibercept. Retina. 2017;37;1859-65.




2020     |     www.medigraphic.com